Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $72.62, for a total transaction of $36,310.00. Following the transaction, the vice president directly owned 79,390 shares in the company, valued at approximately $5,765,301.80. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Tuesday, January 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $84.33, for a total transaction of $42,165.00.

ANI Pharmaceuticals Trading Down 2.8%

Shares of ANIP stock traded down $2.00 during mid-day trading on Friday, reaching $70.49. The company’s stock had a trading volume of 517,923 shares, compared to its average volume of 360,579. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The firm has a market capitalization of $1.58 billion, a PE ratio of 20.98 and a beta of 0.52. The company’s 50 day simple moving average is $79.12 and its 200-day simple moving average is $85.35. ANI Pharmaceuticals, Inc. has a 12-month low of $56.71 and a 12-month high of $99.50.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the first quarter valued at about $28,000. Hantz Financial Services Inc. lifted its stake in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares in the last quarter. Newbridge Financial Services Group Inc. boosted its holdings in ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals in the fourth quarter valued at about $48,000. Finally, State of Wyoming acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at approximately $50,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on ANIP shares. Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim boosted their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $103.43.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.